Disease burden of patients with moderate to severe ulcerative colitis: A French multicenter real-life study (THEFAR).

IF 4 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Digestive and Liver Disease Pub Date : 2024-09-05 DOI:10.1016/j.dld.2024.08.044

Mathurin Fumery, Romain Altwegg, Philippe Aygalenq, Jérome Filippi, Vincent Ghestem, Isabelle Jamonneau, Justin Kirion, Stéphane Bouée, Camille Robert

{"title":"Disease burden of patients with moderate to severe ulcerative colitis: A French multicenter real-life study (THEFAR).","authors":"Mathurin Fumery, Romain Altwegg, Philippe Aygalenq, Jérome Filippi, Vincent Ghestem, Isabelle Jamonneau, Justin Kirion, Stéphane Bouée, Camille Robert","doi":"10.1016/j.dld.2024.08.044","DOIUrl":null,"url":null,"abstract":"Background: Specific studies on the impact of ulcerative colitis (UC) and bowel urgency (BU) on disability and quality of life (QoL) of patients on advanced therapies are missing.Methods: Clinical and therapeutic management data were collected by Gastroenterologists from adult patients with UC treated with advanced therapies. Patients reported outcomes on QoL were collected using patient-reported questionnaires.Results: Forty-one sites enrolled 293 patients. Median age was 42.0 years, median disease duration was 6.0 years. 38.9 % had active disease (partial Mayo score>1). Median treatment duration was 16.9 months. 166 (57.0 %) patients had BU [median UNRS=2] and 78.3 % had fecal incontinence [median Wexner score=8.0]. Moderate to severe disability (IBD-Disk score≥40) was reported in 37.8 % patients. BU patients had a higher Wexner score [10.0 vs 5.2, p < 0.0001] and moderate to severe disability rate (53.7% vs 16.9 %, p < 0.0001), lower QoL and work productivity than those in BU remission: mean EQ-5D-5 L utility [0.846 vs 0.943, p < 0.0001], VAS for self-rated health [66.2 vs 82.1, p < 0.0001], and overall work impairment [35.7% vs 11.3 %, p < 0.0001].Conclusion: The burden of moderate to severe UC, especially in patients with BU, is high. These findings highlight that BU control remains an unmet medical need in UC patients and underscore the need for new innovative treatments.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.dld.2024.08.044","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Specific studies on the impact of ulcerative colitis (UC) and bowel urgency (BU) on disability and quality of life (QoL) of patients on advanced therapies are missing.

Methods: Clinical and therapeutic management data were collected by Gastroenterologists from adult patients with UC treated with advanced therapies. Patients reported outcomes on QoL were collected using patient-reported questionnaires.

Results: Forty-one sites enrolled 293 patients. Median age was 42.0 years, median disease duration was 6.0 years. 38.9 % had active disease (partial Mayo score>1). Median treatment duration was 16.9 months. 166 (57.0 %) patients had BU [median UNRS=2] and 78.3 % had fecal incontinence [median Wexner score=8.0]. Moderate to severe disability (IBD-Disk score≥40) was reported in 37.8 % patients. BU patients had a higher Wexner score [10.0 vs 5.2, p < 0.0001] and moderate to severe disability rate (53.7% vs 16.9 %, p < 0.0001), lower QoL and work productivity than those in BU remission: mean EQ-5D-5 L utility [0.846 vs 0.943, p < 0.0001], VAS for self-rated health [66.2 vs 82.1, p < 0.0001], and overall work impairment [35.7% vs 11.3 %, p < 0.0001].

Conclusion: The burden of moderate to severe UC, especially in patients with BU, is high. These findings highlight that BU control remains an unmet medical need in UC patients and underscore the need for new innovative treatments.

查看原文本刊更多论文

中重度溃疡性结肠炎患者的疾病负担：法国多中心真实生活研究 (THEFAR)。

背景：关于溃疡性结肠炎（UC）和肠紧迫感（BU）对晚期治疗患者的残疾和生活质量（QoL）影响的具体研究尚缺：关于溃疡性结肠炎（UC）和肠紧迫感（BU）对接受晚期治疗的患者的残疾和生活质量（QoL）的影响的具体研究尚属空白：方法：消化科医生收集了接受先进疗法治疗的成年溃疡性结肠炎患者的临床和治疗管理数据。结果：41 个研究机构共招募了 293 名 UC 患者：41个研究机构共招募了293名患者。中位年龄为 42.0 岁，中位病程为 6.0 年。38.9%的患者病情活跃（部分梅奥评分>1）。中位治疗时间为 16.9 个月。166名患者（57.0%）患有BU[UNRS中位数=2]，78.3%患有大便失禁[Wexner评分中位数=8.0]。37.8%的患者患有中度至重度残疾（IBD-Disk评分≥40）。BU患者的Wexner评分[10.0 vs 5.2, p < 0.0001]和中重度残疾率（53.7% vs 16.9 %, p < 0.0001）均高于BU缓解期患者：平均EQ-5D-5 L效用[0.846 vs 0.943，p < 0.0001]，自评健康 VAS [66.2 vs 82.1，p < 0.0001]，以及总体工作损伤 [35.7% vs 11.3%，p < 0.0001]：结论：中重度尿路结石的负担很重，尤其是在患有尿路结石的患者中。这些发现突出表明，BU 控制仍是 UC 患者尚未满足的医疗需求，并强调了对新的创新治疗方法的需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Digestive and Liver Disease 医学-胃肠肝病学

CiteScore

6.10

自引率

2.20%

发文量

632

审稿时长

19 days

期刊介绍： Digestive and Liver Disease is an international journal of Gastroenterology and Hepatology. It is the official journal of Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Pancreas (AISP); Italian Association for Digestive Endoscopy (SIED); Italian Association for Hospital Gastroenterologists and Digestive Endoscopists (AIGO); Italian Society of Gastroenterology (SIGE); Italian Society of Pediatric Gastroenterology and Hepatology (SIGENP) and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease publishes papers on basic and clinical research in the field of gastroenterology and hepatology. Contributions consist of: Original Papers Correspondence to the Editor Editorials, Reviews and Special Articles Progress Reports Image of the Month Congress Proceedings Symposia and Mini-symposia.